Protective Efficiency of Pasteurella multocida A:1 Bacteriophage lysate Vaccine against Homologous and Heterologous Challenge in Poultry | Zendy

Anshuja Nagdive | Zendy; Mayank Rawat | Zendy; Bablu Kumar | Zendy; Ashok Kumar Tiwari | Zendy; Somanath Chavhan | Zendy

Open Access

Protective Efficiency of Pasteurella multocida A:1 Bacteriophage lysate Vaccine against Homologous and Heterologous Challenge in Poultry

Author(s) -

Anshuja Nagdive,

Mayank Rawat,

Bablu Kumar,

Ashok Kumar Tiwari,

Somanath Chavhan

Publication year - 2017

Publication title -

journal of pure and applied microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.149

H-Index - 16

eISSN - 2581-690X

pISSN - 0973-7510

DOI - 10.22207/jpam.11.1.27

Subject(s) - pasteurella multocida , heterologous , bacteriophage , lysis , microbiology and biotechnology , biology , virology , homologous chromosome , bacteria , escherichia coli , genetics , gene

Fowl cholera (FC) caused by serotypes of Pasteurella multocida includes A:1, A:3, A:4 is a highly fatal septicemic disease. Preliminary trials of P. multocida A:1 bacteriophage lysate vaccine against FC was evaluated. Lytic phage and P. multocida ratio was standardized to obtain stable lysate batches. Consequently, three batches of lytic phage preparation were produced; estimation of protein and carbohydrate content amongst batches did not shown any significant variation indicating same batches can be produced by standardized procedure. Protective response trials in poultry with P. multocida A:1, A:3, A:4 against plain lysate and alum adsorbed lysate (1% alum) on vaccinated group showed both homologous and heterologous protection compared with inactivated whole cell group provided only homologous protection. Assessment of antibody response towards P. multocida A:1, A:3, A:4 antigen evaluated by Indirect Haemagglutination test (IHA) reveals presence of protective antibody titer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research